The University of Minnesota Stem Cell Institute supports a variety of basic science research with the aim of clinical translation.
Growing induced pluripotent stem cells with the goal of transforming them into immune cells to treat cancer, insulin-producing beta cells to treat diabetes, and cardiac progenitor cells to treat heart disease. Providing and generating patient-specific iPS cells for gene therapy.
Studying embryonic stem cells, especially the identification of proteins that control pluripotent behavior; finding methods to guide embryonic stem cells to differentiate into specific types of tissues to treat diseases of the heart, kidney, liver, pancreas, and blood-producing system.
Investigating how different types of stem cells become mature neurons (nerve cells) and glial cells (non-nerve tissue of the brain and spinal cord) with the ultimate goal to develop therapies for Parkinson’s disease, Huntington’s disease, multiple sclerosis, stroke, and spinal cord injury.
Isolating and characterizing the cells responsible for organ regeneration, and understanding the processes whereby they become active, with the goal of creating new types of therapy to stimulate regeneration and repair of damaged organs.
Evaluating new methods of immunotherapy using mesenchymal stem cells and their derivatives to improve the survival and performance of allogeneic grafts.
Developing and producing investigational biological agents for use in Phase I and II clinical trials in connection with molecular and cellular therapeutics.
Contact University of Minnesota Stem Cell Institute
Academic Health Center's Communication Office, (612) 624-5100.